To confirm our hypothesis, we treated 5-FU-resistant CRC cells with Rac1 inhibitor 1A-116, noting that doses not compromising viability of CRC cells were sufficient to promote the reversal of morphological changes associated with resistance and re-sensitize resistant cells to 5-FU. Here, RAC1 is linked to colorectal carcinoma.